A team of researchers from the UAB's Mutagenesis Group, led by Dr Jordi Surrallés, has identified one of the mechanisms used by cancer cells to resist chemotherapy.
In his paper, to be published in The EMBO Jorunal, Dr Surrallés describes how proteins of the Fanconi/BRCA pathway recognise the presence of genetic mutations in order to repair them. The researchers also found that alteration of this mechanism makes tumour cells much more sensitive to certain drugs. This discovery will make it possible to develop strategies to make tumours more vulnerable to chemotherapy.